<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03193424</url>
  </required_header>
  <id_info>
    <org_study_id>AHEAD-HNP001</org_study_id>
    <nct_id>NCT03193424</nct_id>
  </id_info>
  <brief_title>Apatinib Combined With Docetaxel in the Treatment of Advanced Esophageal Squamous Cell Carcinoma</brief_title>
  <official_title>A Prospective, Open-label, Randomized Controlled Clinical Study of Apatinib Combined With Docetaxel in the Treatment of Advanced Esophageal Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital of Zhengzhou University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Esophageal cancer is a common malignant tumor in china, occupies the second place of
      malignant tumor morbidity and mortality, the overall 5-year survival rate less than 20%.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Anticipated">December 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double Group Assignment,apatinib plus docetaxel comparison to docetaxel.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>6 months</time_frame>
    <description>The first day of treatment to the date that disease progression is reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Survival (OS)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>the first day of treatment to death or last survival confirm date</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Advanced Esophageal Squamous Carcinoma</condition>
  <arm_group>
    <arm_group_label>Apatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>docetaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>Subjects were randomly divided into two groups,A group:apatinib 500mg/d,po,qd, Docetaxel 75 mg / m2 was administered on day 1 repeated every 21 days until progressive Disease(PD) . B group:Docetaxel 75 mg / m2 was administered on day 1 repeated every 21 days until progressive Disease(PD) .</description>
    <arm_group_label>Apatinib</arm_group_label>
    <arm_group_label>docetaxel</arm_group_label>
    <other_name>Docetaxel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18 years old to 75 years old, male and female is ok.

          -  Esophageal squamous cell carcinoma diagnosed by histopathology and
             immunohistochemistry. At least one treated measurable lesion (spiral CT scan length
             ≥10mm, in line with RESCIST version 1.1 standard requirements);

          -  Patients with advanced esophageal cancer treated by radiotherapy and treatment;

          -  ECOG PS Rating: 0-1 points;

          -  Expected survival ≥12 weeks;

          -  Without molecular targeted drug therapy.

          -  The main organ function is normal, that is to meet the following criteria:

        Blood test:a.HB≥90 g/L；b.ANC≥1.5×109/L；c.PLT ≥80×109/L； Biochemical tests:a.ALB≥30g / L；b.
        ALT和AST&lt;2ULN；ALT and AST &lt;2ULN;c.TBIL≤1.5ULN；Plasma Cr ≤ 1.5ULN;

          -  Subjects volunteered to join the study, signed informed consent, compliance, with
             follow-up.

          -  Researchers believe that patients can benefit.

        Exclusion Criteria:

          -  Patients who have been confirmed to be allergic to apatinib and / or its excipients;

          -  Patients with uncontrollable hypertension (systolic blood pressure&gt; 140 mmHg,
             diastolic blood pressure&gt; 90 mmHg, despite optimal drug therapy), with grade Ⅱ
             myocardial ischemia or myocardial infarction, poor control of arrhythmias (including
             QTc interval male ≥ 450 ms, female ≥470 ms).According to NYHA standard, grade Ⅲ ~ Ⅳ
             heart failure, or cardiac color Doppler ultrasound examination showed left ventricular
             ejection fraction (LVEF) &lt;50%.

          -  Patients with a clear tendency to gastrointestinal bleeding, including the following:
             localized ulcer lesions, and fecal occult blood (++) can not be grouped; 2 months with
             black, hematemesis history;

          -  Coagulation dysfunction (INR&gt; 1.5, APTT&gt; 1.5 ULN), with bleeding tendency;

          -  (Eg, no swallowing, nausea, vomiting, chronic diarrhea and intestinal obstruction,
             etc.) that affect the absorption of oral medications;

          -  The patients with active brain metastases(without medical control) , cancer
             meningitis, spinal cord compression, or screening of imaging CT or MRI examination
             found that the brain or pia mater disease (21 days before the completion of treatment
             and symptoms of stable brain Metastasis patients can be grouped, but the need for
             transcranial MRI, CT or intravenous angiography, confirmed as no cerebral hemorrhage
             symptoms)

          -  Pregnant or lactating women

          -  Subject with other malignancies within 5 years(except the skin basal cell carcinoma
             and cervical in situ cancer that have already cured )

          -  Subject with a history of psychiatric abuse and who can not be abused or have mental
             disorders;

          -  Subject who participated in other drug clinical trials within 4 weeks.

          -  Subject who have received VEGFR inhibitors such as sorafenib, sunitinib;

          -  According to the investigator's judgment, there are serious illnesses that compromise
             the patient's safety or affect the patient's completion of the study;

          -  Researchers think it is not suitable for inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Qingxia Fan</last_name>
    <phone>13939039058</phone>
    <email>fqx2243@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lijie Song</last_name>
    <phone>13939020459</phone>
    <email>lijiesongcn@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>FirstAHZhengzhouU</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qingxia Fan</last_name>
      <phone>139-3903-9058</phone>
      <email>fqx2243@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Lijie Song</last_name>
      <phone>139-3902-0459</phone>
      <email>lijiesongcn@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2017</study_first_submitted>
  <study_first_submitted_qc>June 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2017</study_first_posted>
  <last_update_submitted>June 19, 2017</last_update_submitted>
  <last_update_submitted_qc>June 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital of Zhengzhou University</investigator_affiliation>
    <investigator_full_name>FanQingxia</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

